simendan has been researched along with cardiovascular agents in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (11.43) | 29.6817 |
| 2010's | 21 (60.00) | 24.3611 |
| 2020's | 10 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Riggs, JM | 1 |
| Böttiger, BW; Motsch, J; Rauch, H | 1 |
| Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F | 1 |
| Graudins, A | 1 |
| Cohen, B; Douhal, A; Organero, JA; Rodriguez Padial, L; Santos, L | 1 |
| Fox, CJ; Kaye, AD; Liu, H; Zhang, S | 1 |
| Akgün, T; Biteker, M; Duran, NE; Gökdeniz, T; Gündüz, S; Kahveci, G; Kaya, H; Õzkan, M; Tanboğa, HÎ; Yildiz, M | 1 |
| Beiras-Fernandez, A; Mutlak, H; Scheiermann, P; Weis, F | 1 |
| Bongo, AS; Lazzero, M; Lupi, A; Rognoni, A; Rognoni, G | 1 |
| Bocchi, EA; Carvalho, VO; Cruz, F; Guimarães, GV; Issa, VS; Moura, LZ | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Lyon, AR; Morley-Smith, AC; Omerovic, E | 1 |
| Cully, M | 1 |
| Angadi, U; Chowdhry, MF; Westrope, C | 1 |
| Ata, Y; Eris, C; Turk, T; Yavuz, S | 1 |
| Hajj-Chahine, J | 1 |
| Desimonas, NA | 1 |
| Boysan, E; Cicekcioglu, F; Ersoy, O; Katircioglu, F; Unal, EU; Yay, K; Yener, U | 1 |
| Li, Z; Liu, Y; Ma, S; Wang, X; Xu, W | 1 |
| Acea, AB; Ferrer Hita, JJ; García-González, MJ; Jiménez-Sosa, A; Jorge-Pérez, P; Lacalzada Almeida, JB | 1 |
| Irving, M; Pineda-Sanabria, SE; Robertson, IM; Sun, YB; Sykes, BD | 1 |
| Alexander, JH; Anstrom, KJ; Bokesch, P; Fremes, S; Goodman, SG; Harrington, RA; Harrison, RW; Hay, D; Heringlake, M; Jankowich, R; Leimberger, JD; Levy, JH; Luber, J; Mehta, RH; Meza, J; Parrotta, J; Swartz, M; Toller, W; Tourt-Uhlig, S; Van Diepen, S | 1 |
| Bettex, D; Bouchez, S; Cholley, B; Guarracino, F; Heringlake, M; Kivikko, M; Lomivorotov, VV; Pollesello, P; Rajek, A | 1 |
| Huo, JH; Luo, X; Qiang, H; Wang, ZQ | 1 |
| Andreadou, I; Chavdoula, E; Cokkinos, DV; Davos, CH; Efentakis, P; Farmakis, D; Gioti, K; Iliodromitis, EK; Klinakis, A; Kostomitsopoulos, N; Papapetropoulos, A; Sanoudou, D; Sigala, F; Suter, T; Tasouli, A; Tenta, R; Varela, A; Wenzel, P | 1 |
| Agostoni, P; Cosentino, N; Fracassi, F; Marenzi, G; Niccoli, G; Rebuzzi, A | 1 |
| Bunte, S; Heinen, A; Hollmann, MW; Huhn, R; Mathes, A; Raupach, A; Sixt, SU; Stroethoff, M; Torregroza, C; van de Snepscheut, M | 1 |
| Eagle, SS; Staudt, GE | 1 |
| Ammendola, E; D'Alterio, G; Gravino, R; Masarone, D; Pacileo, G; Petraio, A; Valente, F; Verrengia, M | 1 |
| Adams, V; Barthel, P; Linke, A; Poitz, DM; Schauer, A; Weinbrenner, C | 1 |
| Errigo, V; Martucci, ML; Masarone, D; Melillo, E; Pacileo, G; Pacileo, R; Petraio, A; Pollesello, P | 1 |
| Alper, F; Calik, I; Durur-Subasi, I; Karaman, A; Kose, D; Sirin, B; Yayla, M | 1 |
| Chai, HT; Chen, CH; Chen, YL; Chiang, JY; Sung, PH; Yang, CC; Yip, HK | 1 |
| Abecia, A; Castrodeza, J; Cobo-Marcos, M; Codina, P; de Frutos, F; de Juan-Baguda, J; Diez-Lopez, C; Dobarro, D; Donoso-Trenado, V; Escolar, V; Garcia-Pinilla, JM; Gómez-Otero, I; González-Babarro, E; Gonzalez-Costello, J; Lopez-Fernandez, S; Marzoa-Rivas, R; Melendo-Viu, M; Méndez-Fernández, AB; Moliner-Abós, C; Pastor, F; Rodriguez, M; Ruiz-Bustillo, S; Sagasti-Aboitiz, I; Solé-González, E; Tobar, J; Vaqueriza-Cubillo, D | 1 |
| Aydın, C; Kaplangoray, M | 1 |
11 review(s) available for simendan and cardiovascular agents
| Article | Year |
|---|---|
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
Newer approaches to the pharmacological management of heart failure.
Topics: Calcium Signaling; Cardiotonic Agents; Cardiovascular Agents; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyridazines; Pyridines; Simendan; Tetrazoles | 2006 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents | 2008 |
Cardiovascular pharmacology: an update.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea | 2010 |
The protective effects of levosimendan on ischemia/reperfusion injury and apoptosis.
Topics: Animals; Apoptosis; Cardiovascular Agents; Evidence-Based Medicine; Humans; Hydrazones; Myocardial Reperfusion Injury; Myocardium; Patents as Topic; Potassium Channels; Pyridazines; Simendan; Treatment Outcome | 2011 |
Levosimendan: from basic science to clinical trials.
Topics: Acute Disease; Animals; Calcium Channels; Cardiovascular Agents; Chronic Disease; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Oxygen Consumption; Potassium Channels; Pyridazines; Simendan; Translational Research, Biomedical; Treatment Outcome; Ventricular Function | 2011 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
Takotsubo cardiomyopathy.
Topics: Biomarkers; Cardiac Catheterization; Cardiovascular Agents; Echocardiography; Electrocardiography; Extracorporeal Membrane Oxygenation; Heart-Assist Devices; Hemodynamics; Humans; Hydrazones; Magnetic Resonance Imaging; Prognosis; Pyridazines; Shock, Cardiogenic; Simendan; Takotsubo Cardiomyopathy | 2013 |
Is levosimendan effective in paediatric heart failure and post-cardiac surgeries?
Topics: Age Factors; Benchmarking; Cardiac Surgical Procedures; Cardiovascular Agents; Child, Preschool; Evidence-Based Medicine; Heart Failure; Hemodynamics; Humans; Hydrazones; Pyridazines; Recovery of Function; Simendan; Treatment Outcome; Ventricular Function, Left | 2013 |
Perioperative Use of Levosimendan Improves Clinical Outcomes in Patients After Cardiac Surgery: A Systematic Review and Meta-Analysis.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Cardiovascular Agents; Drug Administration Schedule; Heart Diseases; Humans; Incidence; Intensive Care Units; Length of Stay; Perioperative Care; Renal Replacement Therapy; Respiration, Artificial; Risk Factors; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction.
Topics: Animals; Cardiovascular Agents; Humans; Recovery of Function; Simendan; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
5 trial(s) available for simendan and cardiovascular agents
| Article | Year |
|---|---|
Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial.
Topics: Adult; Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Echocardiography; Female; Heart Ventricles; Humans; Hydrazones; Peripartum Period; Predictive Value of Tests; Pregnancy; Pregnancy Complications, Cardiovascular; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left; Young Adult | 2011 |
Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
Topics: Adult; Brazil; Cardiovascular Agents; Chemoreceptor Cells; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypercapnia; Hyperventilation; Hypoxia; Infusions, Intravenous; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Recombinant Proteins; Respiratory Rate; Simendan; Time Factors; Treatment Outcome | 2013 |
Effectiveness of prophylactic levosimendan in high-risk valve surgery patients.
Topics: Arterial Pressure; Cardiopulmonary Bypass; Cardiovascular Agents; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hemodynamics; Humans; Hydrazones; Hypertension, Pulmonary; Infusions, Parenteral; Pulmonary Artery; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Turkey; Vascular Resistance | 2013 |
Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Cardiovascular Agents; Critical Illness; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Pyridazines; Recovery of Function; Severity of Illness Index; Simendan; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requ
Topics: Administration, Intravenous; Adult; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
19 other study(ies) available for simendan and cardiovascular agents
| Article | Year |
|---|---|
Letter regarding levosimendan in a rat model of severe verapamil poisoning.
Topics: Animals; Antidotes; Cardiotonic Agents; Cardiovascular Agents; Disease Models, Animal; Drug Overdose; Hemodynamics; Hydrazones; Phosphodiesterase Inhibitors; Pyridazines; Rats; Severity of Illness Index; Simendan; Vasodilator Agents; Verapamil | 2009 |
Exploring the ground and excited states structural diversity of levosimendan, a cardiovascular calcium sensitizer.
Topics: Absorption; Calcium; Cardiovascular Agents; Cyclodextrins; Humans; Hydrazones; Pyridazines; Serum Albumin; Simendan; Solutions; Solvents; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Water | 2010 |
Heart failure. Tardy but intact--publication of REVIVE trial results welcomed.
Topics: Access to Information; Cardiovascular Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Information Dissemination; Pyridazines; Research Design; Simendan; Treatment Outcome | 2013 |
eComment. Preoperative levosimendan administration in cardiac surgery patients.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
eComment. Levosimendan in adult patients undergoing cardiac surgery.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
eComment. Consider trying levosimendan.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2013 |
Effects and mechanism analysis of combined infusion by levosimendan and vasopressin on acute lung injury in rats septic shock.
Topics: Acute Lung Injury; Animals; Blood Gas Analysis; Cardiovascular Agents; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Female; HMGB1 Protein; Hydrazones; Lung; Nitrogen Oxides; Norepinephrine; Pyridazines; Rats; Shock, Septic; Simendan; Vasopressins | 2014 |
Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.
Topics: Animals; Calcium; Cardiovascular Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Protein Conformation; Pyridazines; Rats; Simendan; Troponin C; Troponin I | 2016 |
Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice.
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Clinical Decision-Making; Congresses as Topic; Consensus; Evidence-Based Medicine; Heart Diseases; Humans; Patient Selection; Perioperative Care; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Treatment Outcome | 2018 |
Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Topics: Animals; Antibiotics, Antineoplastic; Calcium Signaling; Calcium-Binding Proteins; Cardiotoxicity; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Male; Mammary Neoplasms, Experimental; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats, Wistar; Simendan; Time Factors | 2020 |
Impact of Ca
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ischemic Preconditioning, Myocardial; Isolated Heart Preparation; Large-Conductance Calcium-Activated Potassium Channels; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats, Wistar; Simendan; Small-Conductance Calcium-Activated Potassium Channels | 2019 |
A Tale of 2 Inodilators: Much Ado About Nothing?
Topics: Cardiac Surgical Procedures; Cardiovascular Agents; Child; Heart; Humans; Milrinone; Simendan | 2020 |
Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience.
Topics: Adult; Aged; Ambulatory Care; Cardiovascular Agents; Exercise Tolerance; Female; Functional Status; Heart Failure, Systolic; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Recovery of Function; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2020 |
Pharmacological Pre- and Postconditioning With Levosimendan Protect H9c2 Cardiomyoblasts From Anoxia/Reoxygenation-induced Cell Death via PI3K/Akt Signaling.
Topics: Animals; Apoptosis; Autophagy; Cardiovascular Agents; Cell Hypoxia; Cell Line; Mitochondria, Heart; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocytes, Cardiac; Necrosis; Phosphatidylinositol 3-Kinase; Potassium Channels; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Simendan | 2021 |
Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study.
Topics: Aged; Ambulatory Care; Cardiovascular Agents; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Outpatients; Pilot Projects; Predictive Value of Tests; Recovery of Function; Simendan; Time Factors; Treatment Outcome | 2022 |
Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?
Topics: Animals; Cardiovascular Agents; Glycerol; Oxidative Stress; Rats; Rats, Wistar; Simendan | 2021 |
Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardio-Renal Syndrome; Cardiovascular Agents; Drug Combinations; Fibrosis; Humans; Inflammation; Kidney; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Simendan; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
Topics: Cardiotonic Agents; Cardiovascular Agents; Heart Failure; Humans; Registries; Retrospective Studies; Simendan; Treatment Outcome | 2023 |
[Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure].
Topics: Cardiovascular Agents; Cross-Sectional Studies; Dobutamine; Heart Failure; Humans; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Function, Right | 2023 |